文献速递胃肠外科

黑种人种族与cT2及以上胃腺癌术前化疗使用不足独立相关

Black race is independently associated with underutilization of preoperative chemotherapy in clinical stage T2 or higher gastric adenocarcinoma.
PubMed 文献 · Surgery · 2022-01-04

该研究基于美国国家癌症数据库(2008-2017)分析了13,850例接受手术的cT2及以上胃腺癌患者,比较不同种族间术前化疗的使用情况。结果显示,黑种人种族与接受术前化疗的可能性较低独立相关(OR=0.46, 95%CI: 0.39-0.54)。在<80岁且有保险的患者中,校正多个因素后,黑种人种族仍与较低的术前化疗调整概率相关。

要点

  • 黑种人种族与cT2及以上胃腺癌患者接受术前化疗的可能性较低独立相关(OR=0.46)。
  • 年龄≥70岁、女性、社区机构治疗、非私人保险或无保险、cT4期也与较低术前化疗可能性相关。
  • 在高容量机构治疗、距离机构较远、较高教育和收入水平、cT3期、cN+期与较高术前化疗可能性相关。

核心结论

  • 黑种人种族与cT2及以上胃腺癌患者术前化疗使用不足相关,与已发布的指南不一致。
  • 这种差异的病因是多因素的,纠正根本原因是一个关键的改进领域。

研究设计与样本

  • 研究为基于美国国家癌症数据库(2008-2017)的回顾性队列研究,纳入接受手术的≥cT2胃腺癌的非西班牙裔白种人和黑种人患者,共13,850例(白种人12,161例,黑种人1,689例)。
  • 比较不同种族间术前化疗的给药情况,并校正临床人口学变量。
  • 对<80岁且有保险的患者进行逻辑回归的边际标准化,计算术前化疗的调整概率。

主要发现

  • 黑种人种族与接受术前化疗的可能性低于白种人种族相关(OR=0.46, 95%CI: 0.39-0.54)。
  • 与较低术前化疗可能性相关的其他因素包括年龄≥70岁、女性、社区机构治疗、非私人保险或无保险、cT4期疾病。
  • 与较高术前化疗可能性相关的因素包括高容量机构治疗、距离机构较远、较高教育和收入水平、cT3期疾病、cN+疾病。
  • 在<80岁且有保险的患者中,边际标准化模型显示,无论年龄、保险支付方、机构类型/容量、距离机构距离、cT分期、cN分期、性别和受教育/收入水平如何,黑种人种族均与较低的术前化疗调整概率相关。

关键数值与推荐

  • 共识指南推荐cT2及以上胃腺癌患者接受围手术期化疗和手术。
  • 黑种人种族与接受术前化疗的可能性较低相关(OR=0.46, 95%CI: 0.39-0.54)。

临床怎么用

  • 研究结果提示,对于cT2及以上胃腺癌患者,黑种人种族与术前化疗使用不足相关,与指南推荐不一致,应关注并纠正这一差异。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Consensus guidelines recommend for perioperative chemotherapy and surgery for patients with clinical stage (cT) T2 or greater gastric adenocarcinoma. We compared adherence to guidelines in these patients stratified by race. METHODS: Non-Hispanic White and Black patients with resected ≥cT2 gastric adenocarcinoma were identified within the National Cancer Database (2008-2017). We compared administration of preoperative chemotherapy by race, adjusting for clinicodemographic variables. We performed marginal standardization of logistic regression to calculate adjusted probabilities of administration of preoperative chemotherapy in patients under the age of 80 years with insurance. RESULTS: A total of 13,850 patients were identified (White = 12,161; Black = 1,689). Black race was associated with lower likelihood of receiving preoperative chemotherapy than White race (odds ratio = 0.46, 95% confidence interval: 0.39-0.54). Other factors associated with lower likelihood of preoperative chemotherapy included age ≥70 years, female sex, treatment at community facilities, non-private or no health insurance, and cT4 disease. Factors associated with higher likelihood of preoperative chemotherapy included treatment at high-volume facilities, longer distance to facility, higher education and income levels, cT3 disease, and cN+ disease. In patients <80 years with insurance, marginal standardization models demonstrated that Black race was associated with a lower adjusted probability of receiving preoperative chemotherapy regardless of age, insurance payor, facility type/volume, distance to facility, cT stage, cN stage, sex, and education/income levels. CONCLUSION: Black race was associated with underutilization of preoperative chemotherapy for cT2 or greater gastric cancer, in discordance to published guidelines. The etiology of these disparities is multifactorial, and correcting the root causes represents a critical area for improvement.

来源:Surgery,查看原文。版权归原作者所有。

引用

  1. Elshami M, Hue JJ, Hoehn RS, et al. Black race is independently associated with underutilization of preoperative chemotherapy in clinical stage T2 or higher gastric adenocarcinoma. Surgery. 2022. PMID: 34991911. doi:10.1016/j.surg.2021.11.021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。